Skip to main content
. 2022 Feb 21;33(4):e40. doi: 10.3802/jgo.2022.33.e40

Fig. 3. (A, C) PFS and (B, D) OS in the original cohort, stratified by the residual tumor status. (A, B) Non-residual tumor subgroup; RLNA group (red): full-staging standard surgery with RLNA; non-RLNA group (blue): incomplete-staging surgery without RLNA. (C, D) Optimally debulked subgroup; RLNA group (red); non-RLNA group (blue).

Fig. 3

OS, overall survival; PFS, progression-free survival; RLNA, retroperitoneal lymphadenectomy.